Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma
Latuda Also Gets Delayed Nod
Executive Summary
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.